Clinical trial
O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent…
NCT00004892 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00004892 |
|---|---|
| Title | O6-Benzylguanine and Carmustine Implants in Treating Patients With Recurrent Malignant Glioma |
| Official title | Phase I GLIADEL and Continuous Infusion of Intravenous O6-Benzylguanine Trial in Patients With Recurrent Malignant Glioma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug, Procedure |
| Interventions | O6-benzylguanine, polifeprosan 20 with carmustine implant, conventional surgery |
| Start date | Apr 1, 2000 |
| First posted | May 3, 2004 |
| Last update posted | Feb 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: